牛皮癣,一种流行的慢性炎症性皮肤病,影响全球2-3%的人口,已经超越了它的皮肤病学界限,揭示了与心血管疾病(CVD)的深刻关联。这篇综合综述探讨了银屑病与心血管系统之间的复杂相互作用,深入研究遗传联系,免疫途径,和脂肪组织功能障碍超出常规CVD危险因素。病理生理联系揭示了独特的特征,与其他炎症性皮肤病不同,特别是IL-23和TNF-α的银屑病特异性遗传多态性一直与CVD相关。该评论导航银屑病治疗的复杂景观,应对挑战和未来的方向,特别相关的CVD在银屑病。治疗干预措施,包括TNF抑制剂(TNFi),目前有希望降低心血管风险,甲氨蝶呤可能是一个有利的选择。相反,IL-12/23抑制剂与心血管风险之间的关系仍不确定,而最近的证据表明Janus激酶抑制剂可能没有CVD风险。新的证据支持IL-17和IL-23抑制剂在心血管疾病患者中的安全性和有效性。暗示不断发展的治疗范式。生活方式的修改,他汀类药物,新兴疗法提供了预防策略。然而,目前还缺乏银屑病CVD风险评估的专门筛查指南。Further,不同疾病表型和治疗等级对心血管结局的影响仍然难以捉摸,要求在皮肤病学的交叉点进行持续的研究,风湿病,和心脏病学。总之,解开牛皮癣和心血管疾病之间复杂的联系为患者护理的整体方法提供了基础。专业之间的合作,筛选方法的进步,对治疗影响的细微差别理解对于银屑病患者的全面心血管风险管理至关重要.
牛皮癣是一种皮肤病,不仅影响皮肤,而且与身体脂肪组织的问题有关,会导致炎症和心脏问题.牛皮癣患者的脂肪组织中含有各种免疫细胞,导致肥胖和胰岛素抵抗。研究发现,牛皮癣患者的脂肪组织炎症与心血管问题之间存在很强的联系。脂肪组织释放的特定物质,像瘦素,抵抗素,和脂联素,会影响炎症和心血管健康。牛皮癣患者通常显示这些物质的水平增加。牛皮癣的治疗可能会影响心血管健康。一些研究表明,某些药物,像甲氨蝶呤或肿瘤坏死因子抑制剂,可以降低心脏事件的风险。然而,也有人担心潜在的不利影响,需要进一步的研究来充分了解牛皮癣治疗如何影响心血管结局。管理与银屑病相关的心血管风险,建议定期筛查心脏相关问题。生活方式的改变,比如健康的饮食,压力管理,戒烟,也是必不可少的。此外,特定药物,像他汀类药物和二甲双胍,可能有利于控制银屑病患者的心血管危险因素。尽管在理解银屑病与心血管健康之间的关系方面取得了进展,仍然存在挑战。正在进行研究以制定更好的筛查指南和治疗策略。皮肤科医生之间的合作,风湿病学家,心脏病专家对于解决这种情况的复杂性及其对心脏的影响至关重要。
Psoriasis, a prevalent chronic inflammatory skin disorder affecting 2-3% of the global population, has transcended its dermatological confines, revealing a profound association with cardiovascular diseases (CVD). This comprehensive
review explores the intricate interplay between psoriasis and cardiovascular system, delving into genetic links, immune pathways, and adipose tissue dysfunction beyond conventional CVD risk factors. The pathophysiological connections unveil unique signatures, distinct from other inflammatory skin conditions, in particular psoriasis-specific genetic polymorphisms in IL-23 and TNF-α have consistently been linked to CVD. The
review navigates the complex landscape of psoriasis treatments, addressing challenges and future directions in particular relevance to CVDs in psoriasis. Therapeutic interventions, including TNF inhibitors (TNFi), present promise in reducing cardiovascular risks, and
methotrexate could constitute a favourable choice. Conversely, the relationship between IL-12/23 inhibitors and cardiovascular risk remains uncertain, while recent evidence indicates that Janus kinase inhibitors may not carry CVD risks. Emerging evidence supports the safety and efficacy of IL-17 and IL-23 inhibitors in patients with CVDs, hinting at evolving therapeutic paradigms. Lifestyle modifications, statins, and emerging therapies offer preventive strategies. Dedicated screening guidelines for CVD risk assessment in psoriasis are however lacking. Further, the impact of different disease phenotypes and treatment hierarchies in cardiovascular outcomes remains elusive, demanding ongoing research at the intersection of dermatology, rheumatology, and cardiology. In conclusion, unraveling the intricate connections between psoriasis and CVD provides a foundation for a holistic approach to patient care. Collaboration between specialties, advancements in screening methodologies, and a nuanced understanding of treatment impacts are essential for comprehensive cardiovascular risk management in individuals with psoriasis.
Psoriasis is a skin condition that not only affects the skin but is also linked to issues in the body’s fat tissue, which can lead to inflammation and heart problems. The fat tissue in people with psoriasis contains various immune cells, contributing to obesity and insulin resistance. Research has found a strong connection between inflammation in fat tissues and cardiovascular problems in people with psoriasis. Specific substances released by fat tissue, like leptin, resistin, and adiponectin, can impact inflammation and cardiovascular health. Psoriasis patients often show increased levels of these substances. Treatment for psoriasis may influence cardiovascular health. Some studies suggest that certain medications, like
methotrexate or TNF inhibitors, may lower the risk of heart events. However, there are also concerns about potential adverse effects, and further research is needed to fully understand how psoriasis treatments affect cardiovascular outcomes. To manage the cardiovascular risks associated with psoriasis, regular screening for heart-related issues is recommended. Lifestyle changes, such as a healthy diet, stress management, and smoking cessation, are also essential. Additionally, specific medications, like statins and metformin, may be beneficial in controlling cardiovascular risk factors in people with psoriasis. Despite advancements in understanding the relationship between psoriasis and cardiovascular health, there are still challenges. Research is ongoing to develop better screening guidelines and treatment strategies. Collaboration between dermatologists, rheumatologists, and cardiologists is crucial to address the complex nature of this condition and its impact on the heart.